Wegovy and eye stroke: what the clinical evidence shows

Where the eye-stroke concern with semaglutide actually came from

In July 2024 a retrospective case-series paper published in JAMA Ophthalmology compared rates of NAION among patients at a US academic medical centre. Of those prescribed semaglutide for weight management, 20 developed NAION over roughly two years, a rate meaningfully higher than in matched groups using other weight-loss or diabetes medicines. That comparison drew attention because NAION is not common: in the general population it affects roughly 2–10 people per 100,000 per year. A doubling or trebling of even a small risk is therefore worth taking seriously.

The critical limitation the authors themselves flagged was confounding. People taking semaglutide for weight loss tend to have higher BMI, and higher BMI is itself linked to several NAION risk factors: obstructive sleep apnoea, poorly controlled hypertension and type 2 diabetes. The study could not fully separate the medicine's signal from the background risk carried by the population most likely to use it. That is not a criticism of the research, it is an honest description of what a case series can and cannot show. What it does mean is that the finding calls for prospective investigation, not a straightforward warning label.

If you are already reading about how Wegovy affects vision more broadly, this NAION question sits within a wider picture of ocular monitoring being discussed among clinicians.

What NAION actually is, and why calling it an 'eye stroke' is only partly accurate

NAION occurs when blood flow to the anterior portion of the optic nerve is suddenly reduced, damaging the nerve fibres that carry visual signals to the brain. The result is typically sudden, painless, monocular vision loss, sometimes noticed first thing in the morning. It does share a mechanism with vascular events elsewhere in the body, which is why the colloquial term 'eye stroke' circulates. But it is not caused by the same clot-based process as most brain strokes, and it does not carry the same immediate risks of facial drooping, speech loss or limb weakness that prompt a 999 call for stroke.

That distinction matters because some readers arrive at this topic having seen alarming headlines and assumed semaglutide raises the risk of conventional strokes. The evidence on that point actually runs in the opposite direction: the SELECT cardiovascular outcomes trial found that semaglutide 2.4mg reduced major cardiovascular events in high-risk adults. You can read a fuller breakdown of what the evidence shows on Wegovy and strokes if that is the question you were really asking.

One misconception worth gently setting down: NAION is not caused by raised eye pressure, which is a different condition entirely. If eye pressure is the concern on your mind, that is a separate question with its own evidence base, covered on our page on Wegovy and intraocular pressure.

Risk factors that matter, and what to tell your eye specialist

The structural risk factor most strongly linked to NAION is a condition called 'disc at risk' or small cup-to-disc ratio, meaning the optic nerve head has less anatomical room for the blood vessels supplying it. This is inherited, invisible without an eye examination, and entirely unrelated to weight or lifestyle. People who have already experienced NAION in one eye are at meaningfully elevated risk of it occurring in the other, a fact that becomes clinically relevant if you develop sudden vision changes during treatment with any medicine.

If you are currently using semaglutide (Wegovy) for weight management and notice any sudden change in your vision (even if painless, even if it seems minor) the right step is to contact an eye specialist or your prescriber the same day. Do not wait for a scheduled review. The evidence on Wegovy and eye-related reports continues to grow, and prescribers are increasingly aware of NAION as a question to ask about during treatment.

Rapid weight loss through any method can also sometimes affect fluid distribution in the eye in the short term, though this is distinct from NAION. Some people also notice involuntary muscle movements and wonder whether they are connected to their medication, and our page on Wegovy and eye twitching looks at what the evidence says about that particular symptom. Keeping your prescribing team informed of any new or changed visual symptoms remains the clearest practical guidance available. For a broader look at how semaglutide works and its full side-effect profile, the semaglutide overview covers the current evidence. Readers considering treatment can also explore the weight-loss treatment options that are licensed and available in the UK.

Suspected side effects from any medicine, including any vision changes you believe may be linked to Wegovy, can be reported directly to the MHRA via the Yellow Card scheme, a useful route if you experience something unusual that your clinical team should also know about.

Where the regulatory picture sits and how to stay informed

The MHRA monitors post-marketing safety signals for all medicines licensed in the UK, including Wegovy, which carries a Black Triangle (▼) status indicating it is subject to additional surveillance. As of mid-2026, no specific NAION warning had been added to the UK Summary of Product Characteristics for semaglutide, but the signal identified in the US was under active review by regulators. Prescribers are expected to weigh individual risk (including pre-existing vascular conditions, disc anatomy history if known, and any personal or family history of optic nerve events) when discussing treatment with a patient.

The MHRA publishes drug safety updates as new evidence is assessed; the GOV.UK drug safety update index is the place to check for any formal guidance changes. If you have specific concerns about your eyes and are wondering whether Wegovy is still appropriate for you, that is exactly the kind of question suited to a clinical consultation rather than a web page. Our prescribers at the consultation can review your full medical picture (including any visual history) when assessing suitability for treatment. You can also read about our clinical team and how we work if you want to understand who would be reviewing your case.